Secondary metabolites from Isodon ternifolius (D. Don) Kudo and their anticancer activity as DNA topoisomerase IB and Tyrosyl-DNA phosphodiesterase 1 inhibitors.


Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 27 02 2020
revised: 17 04 2020
accepted: 20 04 2020
pubmed: 30 4 2020
medline: 2 6 2021
entrez: 30 4 2020
Statut: ppublish

Résumé

Based on DNA topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibition of the ethanol extract of the roots of Isodon ternifolius (D. Don) Kudo (Labiatae), its secondary metabolites has been studied. Two new compounds, an ent-abietane diterpenoid isodopene A (1) and a 2,3-seco-triterpene isodopene B (13), along with 25 known compounds were isolated. Their structures were elucidated by spectroscopic analysis and theoretical calculations. The enzyme-based assays indicated that 1 and 13 showed strong (+++) and moderate (++) TOP1 inhibition, respectively. Two chalcone derivatives 11 and 12 were firstly found as dual TDP1 and TOP1 natural inhibitors, and showed synergistic effect with the clinical TOP1 inhibitors topotecan in MCF-7 cells. Compounds 8, 16, and 22 acted as TOP1 catalytic inhibitors with equipotent TOP1 inhibition to camptothecin (++++). Compounds 7 and 8 exhibited significant cytotoxicity against MCF-7, A549, and HCT116 cells with GI

Identifiants

pubmed: 32345458
pii: S0968-0896(20)30353-9
doi: 10.1016/j.bmc.2020.115527
pii:
doi:

Substances chimiques

Antineoplastic Agents, Phytogenic 0
Phosphodiesterase Inhibitors 0
Topoisomerase I Inhibitors 0
Phosphoric Diester Hydrolases EC 3.1.4.-
TDP1 protein, human EC 3.1.4.-
DNA Topoisomerases, Type I EC 5.99.1.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

115527

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hong-Li Zhang (HL)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Yu Zhang (Y)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Xue-Long Yan (XL)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Long-Gao Xiao (LG)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

De-Xuan Hu (DX)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

Qian Yu (Q)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Clinical Pharmacy (School of Integrative Pharmacy, Institute of Integrative Pharmaceutical Research), Guangdong Pharmaceutical University, Guangzhou 510006, China. Electronic address: yuxi3@mail.sysu.edu.cn.

Lin-Kun An (LK)

School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangzhou 510006, China. Electronic address: lssalk@mail.sysu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH